Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (August 2024)
40 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, Aug 28, 2024
Slide 1: Annual Shareholders' Meeting 28 August 2024
Annual Shareholders’ Meeting 28 August 2024
Slide 2: Online Help
Online Help LIVE Notice of m Annual report 2 Fisher &Paykel HEALTHCARE
Slide 3: Your Board
Your Board ea WD Scott St John Lewis Gradon Sir Michael Daniell Pip Greenwood Lisa McIntyre Graham McLean Neville Mitchell Cather Simpson 3 Fisher & Paykel HEALTHCARE
Slide 4: Agenda
Agenda *« Chair’s Address and Board Subcommittee Updates ¢ Managing Director and Chief Executive Officer’s Address * Financial Statements * Resolutions *« Voting * General Questions Fisher & Paykel HEALTHCARE
Slide 5: Scott St John, Board Chair
Scott St John Board Chair HEALTHCARE
Slide 6: Constant currency growth rates for revenue and net profit after tax
Constant currency growth rates for revenue and net profit after tax
Slide 7: New applications: NIV, nasal high flow, surgical
• • • *New applications = Noninvasive ventilation (NIV), nasal high flow, surgical
Slide 8: Homecare product group
Homecare product group 3 Oo Fisher &Paykel HEALTHCARE
Slide 9: Scott St John, Board Chair
Scott St John Board Chair HEALTHCARE
Slide 10: Dividend history
Dividend 10 Total dividend for the year increased by 2% to 41.5 cps The company’s dividend reinvestment plan remains available for eligible shareholders with a 3% discount 45 40 20 Dividend (CPS) 10 ‘ad fe 2013 ° 2014 DIVIDEND HISTORY ° o , | 2015 2016 «2017: «2018 = 2019 mlinterim cps m™Final cps °
Slide 11: Expanding our global reach
Expanding our global reach September 2023: We held the official opening ceremony for our third building in Tijuana, Mexico. July 2024: Our team in Guangzhou, China with the first Airvo 2 off the manufacturing line. S N Fisher&.Paykel HEALTHCARE
Slide 12: Environmental and social responsibility
Environmental and social responsibility 2 Fisher Paykel HEALTHCARE
Slide 13: Your Board
Your Board ea WD Scott St John Lewis Gradon Sir Michael Daniell Pip Greenwood Lisa McIntyre Graham McLean Neville Mitchell Cather Simpson B Fisher&.Paykel HEALTHCARE
Slide 14: Appointment of Mark Cross
Appointment of Mark Cross 14 Effective 1 October 2024 Will chair the Audit & Risk Committee with Neville’s move to Board Chair Fisher&.Paykel HEALTHCARE
Slide 15: Scott St John, Board Chair
Scott St John Board Chair 15 Fisher&.Paykel HEALTHCARE
Slide 16: Neville Mitchell
Neville Mitchell Audit & Risk Committee Chair Incoming Board Chair 16 Fisher&.Paykel HEALTHCARE
Slide 17: Lisa McIntyre
Lisa McIntyre 7 People & Remuneration Committee Chair Fisher&.Paykel HEALTHCARE
Slide 18: Sir Michael Daniell
Sir Michael Daniell Quality, Safety & Regulatory Committee Chair 18 Fisher&.Paykel HEALTHCARE
Slide 19: Lewis Gradon
Lewis Gradon Managing Director and CEO 6 Fisher & Paykel HEALTHCARE
Slide 20: FY25 first half outlook
FY25 first half outlook At 31 July exchange rates*, guidance assumptions for the first half of the 2025 financial year include a continuation of the current trading environment and result in: * Revenue in the range of approximately $940 million to $950 million. * Net profit after tax in the range of
Slide 21: FY25 full year outlook - revenue
FY25 full year outlook - revenue At 31 July exchange rates*, the company expects: * Operating revenue to be in the range of approximately $1.9 billion to $2.0 billion. Hospital contributors * Changing clinical practice * New product introductions *« Northern Hemisphere seasonal hospitalisation rates
Slide 22: New product introductions
New product introductions HOSPITAL HOMECARE F&P Solo™ mask launched into NZ, Australia, Canada and certain European countries in H2 FY 24, followed by the US in H1 FY25. The F&P 950™ System launched into the US in H1 FY25. F&P Airvo 3™ nasal high flow device F&P Nova Micro™ mask launched into NZ lau
Slide 23: FY25 full year outlook - net profit after tax
FY25 full year outlook - net profit after tax At 31 July exchange rates*, the company expects: . thi * Full year net profit after tax to be in the range of Underlying NPAT* history approximately $320 million to $370 million. $524.2M Impacted by: * Revenue (as discussed on the previous slides) $376.9
Slide 24: Long term gross margin and operating margin targets
70% 40% 60% 35% 30% 50% 25% 40% 20% 30% 15% 20% 10% 10% 5% 0% 0% FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24* FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24* Long Term Gross Margin target Long Term Operating Margin target
Slide 25: Continuous improvement at F&P
Continuous improvement at F&P Continuous improvement is embedded across business functions and regions, contributing to our growth. Global number of Cl suggestions FY24: 7,000 Global number of Cl initiatives executed FY24: 4,170 Fisher & Paykel 2s HEALTHCARE
Slide 26: Applications outside of invasive ventilation
Invasive Noninvasive Hospital Obstructive Sleep Home Respiratory Respiratory Support Anesthesia Apnea Support Ventilation Ventilation Infant Care Surgical Applications outside of invasive ventilation
Slide 27: Long-term growth aspirations illustration
The image above is an illustration of the company’s long-term growth aspirations. It is not a graph and should not be interpreted as being indicative of levels of revenue or profitability in the short term.
Slide 28: Lewis Gradon
Lewis Gradon Managing Director and CEO os Fisher & Paykel HEALTHCARE
Slide 29: Scott St John, Board Chair
Scott St John Board Chair 29 Fisher&.Paykel HEALTHCARE
Slide 30: Financial statements
Financial statements * Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor’s report or the company’s 2024 annual report. ¢ There will be an opportunity to ask any general questions once all items on the agenda have been considered. 30 Fisher & Payk
Slide 31: Resolutions
Resolutions Re-election of Sir Michael Daniell Election of Graham McLean Auditor’s Remuneration Issue of Performance Share Rights Issue of Options QRWN > Fisher & Paykel HEALTHCARE
Slide 32: How to vote online
How to vote online 32 LIVE Virtual Meeting Voting box : Question box OBB0200220) Notice of meeting Annual repo Fisher &Paykel HEALTHCARE
Slide 33: Resolution 1: Re-election of Sir Michael Daniell
Resolution 1: Re-election of Sir Michael Daniell That Sir Michael Daniell, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220 3
Slide 34: Resolution 2: Election of Graham McLean
Resolution 2: Election of Graham McLean That Graham McLean, who being eligible, offers himself for election, be elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220 34 Fisher & Paykel HEALTHCARE
Slide 35: Graham McLean
Graham McLean Director 35 Fisher & Paykel HEALTHCARE
Slide 36: Resolution 3: Auditor's Remuneration
Resolution 3: Auditor’s Remuneration That the Directors be authorised to fix the fees and expenses of PwC as the Company’s auditor. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220 Fisher & Paykel HEALTHCARE 36
Slide 37: Resolution 4: Issue of Performance Share Rights
Resolution 4: Issue of Performance Share Rights That approval be given for the issue of up to 100,000 performance share rights under the Fisher & Paykel Healthcare 2022 Performance Share Rights Plan to Lewis Gradon, Managing Director and Chief Executive Officer of the Company. Click “Submit Vote” to
Slide 38: Resolution 5: Issue of Options
Resolution 5: Issue of Options That approval be given for the issue of up to 190,000 options under the Fisher & Paykel Healthcare 2022 Share Option Plan to Lewis Gradon, Managing Director and Chief Executive Officer of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Link Mar
Slide 39: Fisher &
39 Fisher & Paykel HEALTHCARE
Slide 40: Thank you for attending today's Annual Shareholders' Meeting
Thank you for attending today’s Annual Shareholders’ Meeting 4 Fisher & Paykel HEALTHCARE
Fisher & Paykel Healthcare — Shareholder Meeting (August 2024) on 6ix